63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
Baricitinib may effectively treat oral lichen planus.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations
,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
October 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
32 citations
,
April 2016 in “Journal of Investigative Dermatology” STAT5 activation is crucial for starting the hair growth phase.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.